James E Vath

USPTO Granted Patents = 27 (Patent Applications = 30)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 11)

Average Co-Inventor Count = 1.6

ph-index = 5

Forward Citations = 127(Granted Patents)

Company Filing History:

Vanderbilt University

patents

1 out of 43

Praecis Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2019

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10406134 - Methods of treating an overweight subject (2019-09-10),

2. 10259796 - Oxaspiro[2.5]octane derivatives and analogs (2019-04-16),

3. 10231946 - Methods of treating ischemic organ damage and other disorders (2019-03-19),

4. 10220015 - Fumigillol compounds and methods of making and using same (2019-03-05),

5. 10064839 - Methods of treating liver diseases (2018-09-04),

6. 10023561 - Fumagillol heterocyclic compounds and methods of making and using same (2018-07-17),

7. 9944613 - Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same (2018-04-17),

8. 9925166 - Methods of treating an overweight or obese subject (2018-03-27),

9. 9895339 - Fumigillol compounds and methods of making and using same (2018-02-20),

10. 9849106 - Methods of treating impaired wound healing (2017-12-26),

11. 9839622 - Methods of treating hypothalamic obesity (2017-12-12),

12. 9701651 - Methods of treating an overweight or obese subject (2017-07-11),

13. 9682965 - Fumagillol heterocyclic compounds and methods of making and using same (2017-06-20),

14. 9656979 - Methods of treating an overweight or obese subject (2017-05-23),

15. 9649293 - Methods of treating an overweight subject (2017-05-16),

Title: Innovations and Contributions of James E. Vath

Introduction

James E. Vath is a distinguished inventor based in Lynnfield, MA, with a remarkable portfolio of 27 patents to his name. His work primarily focuses on innovative methods related to weight management and pharmaceutical formulations aimed at treating various disorders.

Latest Patents

Among his most recent contributions, Vath has developed a patent for "Methods of treating an overweight subject." This invention outlines strategies for inducing weight loss and enhancing glucose tolerance through the administration of a MetAP2 inhibitor. Another significant patent is for "Oxaspiro[2.5]octane derivatives and analogs," which encompasses the creation of these derivatives and analogs, along with their methods of preparation, intermediates, pharmaceutical compositions, and therapeutic applications for conditions such as obesity.

Career Highlights

James E. Vath has had a successful career collaborating with notable institutions. He has contributed to the field of medical research and pharmaceutical development while working with Zafgen, Inc. and Vanderbilt University. His expertise in developing therapeutic methods has led to advancements in the treatment of overweight and obesity.

Collaborations

Throughout his career, Vath has collaborated with other esteemed professionals, including Thomas Edward Hughes and Robert Zahler. These partnerships have played a crucial role in enhancing the research outcomes and expanding the potential applications of his inventions.

Conclusion

James E. Vath's innovative contributions to the fields of weight management and pharmacology underscore his commitment to improving health outcomes. His extensive patent portfolio not only reflects his inventive spirit but also signals the impact of his work on current and future medical treatments.

This text is generated by artificial intelligence and may not be accurate.